These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 34357500)

  • 21. Brigatinib: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging strategies to target RAS signaling in human cancer therapy.
    Chen K; Zhang Y; Qian L; Wang P
    J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
    Iska S; Alley EW
    Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
    Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F
    Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
    Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adagrasib: First Approval.
    Dhillon S
    Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
    Soulières D; Gelmon KA
    J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060
    [No Abstract]   [Full Text] [Related]  

  • 32. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
    Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
    Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceritinib: first global approval.
    Dhillon S; Clark M
    Drugs; 2014 Jul; 74(11):1285-91. PubMed ID: 24980964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.